[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 274, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "CFO, COO & Principal Accounting Officer", "fiscalYear": 2023, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 86162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 60, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 67, "title": "Chief Technology Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd D.C. Anderman J.D.", "title": "Chief Legal Officer & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Rubenstein M.S.", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Meyers", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Kaiser M.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.34, "open": 7.33, "dayLow": 7.25, "dayHigh": 7.65, "regularMarketPreviousClose": 7.34, "regularMarketOpen": 7.33, "regularMarketDayLow": 7.25, "regularMarketDayHigh": 7.65, "payoutRatio": 0.0, "beta": 1.332, "forwardPE": -7.392157, "volume": 1332221, "regularMarketVolume": 1332221, "averageVolume": 1010106, "averageVolume10days": 1666560, "averageDailyVolume10Day": 1666560, "bid": 5.49, "ask": 9.38, "bidSize": 2, "askSize": 2, "marketCap": 1199025920, "fiftyTwoWeekLow": 4.06, "fiftyTwoWeekHigh": 11.775, "priceToSalesTrailing12Months": 18.81622, "fiftyDayAverage": 7.7634, "twoHundredDayAverage": 8.257075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 882708736, "profitMargins": 0.0, "floatShares": 124121633, "sharesOutstanding": 159022000, "sharesShort": 11601339, "sharesShortPriorMonth": 11157592, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.0738, "heldPercentInsiders": 0.01135, "heldPercentInstitutions": 0.85111, "shortRatio": 11.91, "shortPercentOfFloat": 0.074099995, "impliedSharesOutstanding": 159022000, "bookValue": 1.999, "priceToBook": 3.771886, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -193506000, "trailingEps": -1.22, "forwardEps": -1.02, "enterpriseToRevenue": 13.852, "enterpriseToEbitda": -5.205, "52WeekChange": -0.2250771, "SandP52WeekChange": 0.12744582, "quoteType": "EQUITY", "currentPrice": 7.54, "targetHighPrice": 22.0, "targetLowPrice": 14.0, "targetMeanPrice": 17.77778, "targetMedianPrice": 17.0, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 392102016, "totalCashPerShare": 2.466, "ebitda": -169595008, "totalDebt": 75783000, "quickRatio": 10.269, "currentRatio": 10.664, "totalRevenue": 63723000, "debtToEquity": 24.032, "revenuePerShare": 0.403, "returnOnAssets": -0.30525, "returnOnEquity": -0.95212, "grossProfits": -69538000, "freeCashflow": -87587752, "operatingCashflow": -134676992, "revenueGrowth": 0.154, "grossMargins": -1.09125, "ebitdaMargins": -2.6614401, "operatingMargins": -2.9607198, "financialCurrency": "USD", "symbol": "OCUL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 2.724793, "regularMarketPrice": 7.54, "corporateActions": [], "postMarketTime": 1741391671, "regularMarketTime": 1741381201, "exchange": "NGM", "messageBoardId": "finmb_41955650", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1406295000000, "postMarketChangePercent": 2.78515, "postMarketPrice": 7.75, "postMarketChange": 0.21, "regularMarketChange": 0.19999981, "regularMarketDayRange": "7.25 - 7.65", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1010106, "fiftyTwoWeekLowChange": 3.48, "fiftyTwoWeekLowChangePercent": 0.85714287, "fiftyTwoWeekRange": "4.06 - 11.775", "fiftyTwoWeekHighChange": -4.2349997, "fiftyTwoWeekHighChangePercent": -0.35966027, "fiftyTwoWeekChangePercent": -22.50771, "earningsTimestamp": 1741003200, "earningsTimestampStart": 1746442740, "earningsTimestampEnd": 1746792000, "earningsCallTimestampStart": 1741006800, "earningsCallTimestampEnd": 1741006800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.22, "epsForward": -1.02, "epsCurrentYear": -1.215, "priceEpsCurrentYear": -6.205761, "fiftyDayAverageChange": -0.22340012, "fiftyDayAverageChangePercent": -0.028776066, "twoHundredDayAverageChange": -0.71707535, "twoHundredDayAverageChangePercent": -0.086843744, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "displayName": "Ocular Therapeutix", "trailingPegRatio": null, "__fetch_time": "2025-03-08"}]